Sirolimus


Other name

-

International/Other brands

Rapamune

Groups

Approved

Structure

Prescription products

NameDosageStrengthRouteLabeller
Gd-sirolimusTablet5 mgOralGenmed A Division Of Pfizer Canada Inc
Gd-sirolimusSolution1.0 mgOralGenmed A Division Of Pfizer Canada Inc
Gd-sirolimusTablet2 mgOralGenmed A Division Of Pfizer Canada Inc
Gd-sirolimusTablet1.0 mgOralGenmed A Division Of Pfizer Canada Inc
RapamuneTablet, coated2 mgOralPfizer
RapamuneTablet, sugar coated1 mg/1OralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.
RapamuneTablet, sugar coated1 mg/1OralCardinal Health
RapamuneTablet1.0 mgOralPfizer
RapamuneTablet, coated0.5 mgOralPfizer
RapamuneTablet, coated1 mgOralPfizer

Target

-

Description

A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to immunophilins. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.

Indications

Sirolimus inhibits T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin IL-2, IL-4, and IL-15) stimulation by a mechanism that is distinct from that of other immunosuppressants. Sirolimus also inhibits antibody production. In cells, sirolimus binds to the immunophilin, FK Binding Protein-12 (FKBP-12), to generate an immunosuppressive complex. The sirolimus:FKBP-12 complex has no effect on calcineurin activity. This complex binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This inhibition suppresses cytokine-driven T-cell proliferation, inhibiting the progression from the G1 to the S phase of the cell cycle.

Other indications

-

Mechaism of action

-

Absorption

-

Metabolism

-

Toxicity

-